Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70202 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kaili Liao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Immune Checkpoint Inhibitors, SARS-CoV-2. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We conducted a retrospective analysis of cancer patients who received PD‐1/PD‐L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune‐related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter‐subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi‐squared, and Mann–Whitney U ‐tests.
Result
The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD‐1/PD‐L1 inhibitors, and alterations in hepatic and renal function ( p > 0.05).
Conclusion
Our findings suggest that infection with COVID‐19 does not significantly impact the safety of PD‐1/PD‐L1 inhibitors in cancer patients. Most cancer patients used PD‐1/PD‐L1 inhibitors during COVID‐19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
- The 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- The 2nd Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
ORCID-Profile: Long Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liao, K., Cheng, J., Hu, Y., Zhang, B., Huang, P., Liu, J., Zhang, W., Hu, H., Bai, X., Qian, Y., Guo, D., Ai, K., Zhu, Y., & Huang, L. (2024). Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.70202
Vancouver
Liao K, Cheng J, Hu Y, Zhang B, Huang P, Liu J, et al. Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study. Cancer Medicine. 2024. doi:10.1002/cam4.70202
BibTeX
@article{Liao2024,
author = {Liao, Kaili and Cheng, Jinting and Hu, Yujie and Zhang, Beining and Huang, Peng and Liu, Jie and Zhang, Wenyige and Hu, Huan and Bai, Xinyi and Qian, Yihui and Guo, Daixin and Ai, Kun and Zhu, Yuchen and Huang, Long},
title = {Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70202}
}
EUVIMED